Ibrutinib/rituximab versus placebo/rituximab in Waldenström's macroglobulinemia (WM): Results of a randomized phase 3 trial Meeting Abstract
| Authors: | Buske, C.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C. S.; Palomba, M. L.; Matous, J. V.; Shustik, C.; Kastritis, E.; Treon, S. P.; Li, J.; Salman, Z.; Graef, T.; Dimopoulos, M. A.; on behalf of the iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia |
| Abstract Title: | Ibrutinib/rituximab versus placebo/rituximab in Waldenström's macroglobulinemia (WM): Results of a randomized phase 3 trial |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 41 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2018 Sep 28-Oct 2 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2018-09-01 |
| Start Page: | 252 |
| Language: | English |
| ACCESSION: | WOS:000446816500614 |
| PROVIDER: | wos |
| PUBMED: | 30261496 |
| DOI: | 10.1159/000492737 |
| Notes: | Meeting Abstract: V759 -- Source: Wos |
